

FDA's Communication of Drug Safety

Steven Galson, MD, MPH
Director, Center for Drug Evaluation and Research
December 7-8, 2005
Welcome – Opening Remarks

FDA's Communication of Drug Safety

Paul Seligman, MD, MPH

**Director, Office of Pharmacoepidemiology and Statistical
Science**

Center for Drug Evaluation and Research

December 7-8, 2005

Moderator

Questions to Consider

1. What are the strengths and weaknesses of the following communication tools?

Patient Information Sheets

Healthcare Professional Information Sheets

Public Health Advisories

Press Releases

Medwatch Listserv Safety Updates

Patient Safety News

CDER Internet Sites

Questions to Consider (cont)

2. What information is available about awareness, use, and perceptions of the effectiveness of the communication tools by healthcare professionals and by the public in general?
3. Do these tools provide the right kind and amount of risk and other information that health care professionals need to make informed decisions about whether to prescribe drug products, and that the public needs to make informed decisions about whether to use those products?

Questions to Consider (cont)

4. How easily accessible and understandable are FDA's Internet-based sources of drug information?
5. To what extent do CDER's patient-focused communication tools provide useful information for people of low health literacy skills.
6. What mechanism should CDER consider to convey risk information to special populations (e.g., elderly, non-English speaking)?